{"nctId":"NCT00378014","briefTitle":"Preservation of Renal Function in Liver Transplant Recipients With Certican Therapy","startDateStruct":{"date":"2006-08"},"conditions":["Liver Transplantation"],"count":276,"armGroups":[{"label":"Everolimus","type":"EXPERIMENTAL","interventionNames":["Drug: basiliximab","Drug: CNI"]},{"label":"Calcineurin Inhibitor (CNI)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: everolimus","Drug: basiliximab","Drug: CNI"]}],"interventions":[{"name":"everolimus","otherNames":["certican"]},{"name":"basiliximab","otherNames":["simulect"]},{"name":"CNI","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Males or females 18 - 70 years old\n* Liver transplant recipient (living or deceased donor)\n* Patients in whom an allograft biopsy will not be contraindicated\n\nExclusion Criteria:\n\n* Recipients of multiple solid organ transplants or patients that have already received a transplant in the past\n* HCV positive patients who need an active anti-viral treatment (HCV- positive patients without active antiviral treatment are allowed)\n* HIV positive patients\n* Patients who are breast feeding\n* Patients with a current severe systemic infection\n* Presence of any hypersensitivity to drugs similar to Certican® (e.g. macrolides)\n* Preexisting (i.e. not related to CNI-damage) renal dysfunction that, according to the judgment of the investigator, will not significantly improve after transplantation (i.e., for example, patients that are expected to have a cGFR below 50ml/min at 4 weeks post transplantation)\n* Patients that have received Simulect prior to this study.\n* Other protocol-defined inclusion/exclusion criteria may apply.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"70 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Calculated Glomerular Filtration Rate (cGFR)","description":"This outcome measure evaluated renal function by assessing the calculated GFR based on the Cockcroft-Gault formula.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"87.9","spread":"32.0"},{"groupId":"OG001","value":"84.1","spread":"34.9"}]}]}]},{"type":"SECONDARY","title":"Incidence of Efficacy Failure","description":"Efficacy failure was defined as the composite endpoint of biopsy-proven acute rejection (BPAR), graft loss, death, lost to follow-up (from any reason), whichever occurred first. Incidence of efficacy failure was estimated using crude rate estimation (relative frequency).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"20.8","spread":null},{"groupId":"OG001","value":"20.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of the Need for a Change in the Immunosuppressive Regimen","description":"The incidence of any changes in the immunosuppressive regimen other than allowed in the study protocol (for example, introduction of Mycophenolic acid (MPA) or sirolimus) was estimated using crude rate estimation (relative frequency).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"80.2","spread":null},{"groupId":"OG001","value":"73.5","spread":null}]}]}]},{"type":"SECONDARY","title":"Incidence of Renal Deterioration","description":"Renal deterioration was defined as a decrease by ≥25% in the cGFR compared to baseline and confirmed by one consecutive measurement. The analysis of this outcome measure was omitted because of missing relevance.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Renal Function (cGFR)","description":"This outcome measure evaluated renal function by assessing the calculated GFR based on the Cockcroft-Gault formula.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"88.7","spread":"31.0"},{"groupId":"OG001","value":"82.9","spread":"29.4"}]}]}]},{"type":"SECONDARY","title":"Incidence of Treated BPAR","description":"The incidence of treated BPAR was estimated using crude rate estimation (relative frequency).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"13.5","spread":null},{"groupId":"OG001","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Patient and Graft Survival","description":"Patient survival was defined as the time from date of randomization to date of death from any cause. If a patient was not known to have died, patient survival was censored as the date of last contact. Graft survival was defined as the time from the date of randomization to the date of graft loss. If a patient was not known to suffer from a graft loss or died without graft loss, time to graft loss was censored with date of last contact or date of death, respectively. Patient and graft survival were analyzed using the Kaplan Meier method.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3","spread":null},{"groupId":"OG001","value":"4.1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.2","spread":null},{"groupId":"OG001","value":"2.1","spread":null}]}]}]},{"type":"SECONDARY","title":"Hepatitis C Virus (HCV) Replication in HCV-positive Patients","description":"HCV ribonucleic acid (RNA) was measured by real time reverse transcriptase polymerase chain reaction (PCR; copies per mL).","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"64.5","spread":null},{"groupId":"OG001","value":"55.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"0.0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"44.7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"62.9","spread":null},{"groupId":"OG001","value":"38.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","spread":null},{"groupId":"OG001","value":"13.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"35.5","spread":null},{"groupId":"OG001","value":"48.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death","description":"Patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"98","spread":null},{"groupId":"OG001","value":"96","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"67","spread":null},{"groupId":"OG001","value":"58","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"4","spread":null},{"groupId":"OG001","value":"4","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Patients Who Experienced Adverse Events, Serious Adverse Events and Death","description":"Patients with all (serious and non-serious) adverse events, serious adverse events and death were reported.","paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"41","spread":null},{"groupId":"OG001","value":"40","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"26","spread":null},{"groupId":"OG001","value":"28","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"2","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":67,"n":101},"commonTop":["DIARRHOEA","NASOPHARYNGITIS","HYPERTENSION","OEDEMA PERIPHERAL","URINARY TRACT INFECTION"]}}}